Ask a clinical question at the bedside and a growing number of tools will answer it — some purpose-built for healthcare, some general chatbots pressed into service. This page compares the purpose-built ones as a capability matrix: it places their documented attributes side by side, ties the strongest independent evidence to the tools it actually tested, and declines to name a single best product. As of July 2026. The category sits on top of two ideas worth knowing first — the clinical LLM and retrieval-augmented generation, the technique that lets a model answer from a curated evidence base rather than from memory alone.
How to use this comparison
The honest difficulty in this category is that the ground is moving under it. The general-purpose models improve every few months, and the specialized tools are re-tuned against them. A ranking frozen today would mislead by next quarter. A matrix of attributes — grounding, citations, access, evidence base — ages more gracefully, because those design choices change more slowly than leaderboard positions. Read each attribute against the study design behind it, using the questions in our guide on how to read an AI validation study.
The independent result everyone should read first
One blinded benchmark reshaped how this category should be discussed. It pitted two specialized clinical tools — OpenEvidence and UpToDate Expert AI — against three general-purpose frontier models (GPT-5.2, Gemini 3.1 Pro, and Claude Opus 4.6), across three evaluations: 500 knowledge-test questions, 500 items measuring alignment with clinicians, and 100 real, de-identified physician queries judged by 12 blinded reviewers 1. The finding was blunt: "Frontier LLMs outperformed clinical AI tools in all three evaluations" 1. More striking still, on the real physician queries the specialized tools "performed comparably to auto-enabled Google Search AI Overview" 1 — a general consumer feature.
Two cautions keep that result in proportion. A benchmark measures answer quality under test conditions, rather than safety in a live clinic, and it does not capture the workflow, the audit trail, or the medico-legal comfort of a sourced answer that a clinician can open and check. And leaderboard position is the fastest-changing attribute in this whole comparison. Still, the direction is clear enough to retire the assumption that a purpose-built clinical tool automatically beats a well-prompted general model. The running numbers behind this field live in our LLM medical benchmark results tracker.
What a benchmark measures, and what it hides
A benchmark answers a narrow question well: given a fixed set of graded items, which system produces the better answers under blinded review. It is close to silent on almost everything a deployment decision turns on. It does not tell you whether an answer arrived with a citation the clinician could open, how the tool behaves on the long tail of rare presentations, or whether the tool's confidence tracks its correctness. The blinded study built one of its three stages from real, de-identified physician queries 1 precisely because a knowledge-test question and a live question diverge — a system can ace a multiple-choice item and stumble on the underspecified, half-formed question a clinician actually types at 3 a.m. Read a leaderboard as a ceiling on curated tasks, and pair it with the grounding attributes below before drawing any conclusion about bedside use.
The capability matrix
Every filled cell cites its source. A dash means the attribute was not stated in the sources cited here — read it as "confirm with the vendor," not as "absent."
| Attribute | OpenEvidence | UpToDate Expert AI | ClinicalKey AI | DynaMed (Dyna AI) | General frontier LLMs |
|---|---|---|---|---|---|
| Positioning | Clinician Q&A tool 5 | Clinician Q&A over graded content 4 | Point-of-care clinician tool 2 | Point-of-care clinician tool 3 | General assistant 1 |
| Retrieval over a curated evidence base | — | — | Yes, RAG + vector search 2 | Evidence-graded content 3 | No curated base by default 1 |
| Citations linked to sources | — | — | Yes, with real-time validation 2 | — | Varies by model 1 |
| Documented hallucination-control process | — | — | Clinician-in-the-loop review 2 | — | — |
| Evaluated in the blinded benchmark | Yes 1 | Yes 1 | — | — | Yes 1 |
The sparse cells for OpenEvidence and UpToDate Expert AI are deliberate: both are built to answer with sourced references, but this matrix fills only what a cited source states, and their public product pages did not yield those specifics under the access used here. The point is method, not judgment — where a cell is empty, ask the vendor to document it.
Where the tools genuinely differ: grounding
Strip away the leaderboard and the durable difference is grounding — whether an answer is generated from a curated, auditable evidence base or from the model's parameters. ClinicalKey AI documents the fuller version of the grounded approach: retrieval over "copyright-cleared" content with "citations linked to published evidence," a "real-time citation validation" step, and a "clinician-in-the-loop" evaluation intended to "minimize hallucinations and bias common in traditional LLMs" 2. DynaMed pairs evidence-graded content with a generative "Dyna AI" feature 3. The general-purpose models, by contrast, carry no built-in curated base — their strength is fluency and reasoning, and their characteristic risk is a confident answer with no source behind it, the failure mode covered in AI hallucination in clinical contexts.
This is why a benchmark win and a safe bedside tool are different achievements. A model can top the leaderboard 1 and still hand a clinician an unsourced claim; a lower-scoring tool that always shows its citations may be the safer instrument precisely because it lets the clinician verify. The retrospective finding that GPT-4 outscored emergency physicians on diagnostic accuracy 7 belongs in the same frame: impressive on a test set, and no substitute for evaluation in the messy live setting where sourcing and oversight decide safety.
Where general models help and where they hurt
The case for a general-purpose model is genuine: fluent synthesis, breadth across specialties, and — on the evidence of the blinded benchmark 1 and the retrospective study where GPT-4 outscored emergency physicians 7 — strong raw performance. The case against using one unaugmented is equally genuine. With no curated base, the same model that reasons well can fabricate a citation or a dose with total fluency, and nothing on the screen marks the difference between a grounded answer and an invented one. So the grounded, cited tools and the raw models are best read as answering different needs — breadth and speed on one side, auditability on the other — rather than as points on a single quality axis. A sensible deployment often uses both: a general model to draft or explore, and a grounded tool to confirm anything that will touch a decision. Whichever you reach for, the clinician remains the point of judgment, and the tool's job is to make its reasoning checkable rather than to be trusted blind.
The evidence base is the product
For the grounded tools, the model is almost the least interesting part; the evidence base it retrieves from is what a clinician is actually trusting. Three questions decide its quality. What is in it — ClinicalKey AI documents drawing on specialty-society guidelines and high-impact journals 2, a different provenance from a general model's undocumented training mixture. How current it is — ClinicalKey AI states its content is refreshed daily 2, which matters in fields where guidance turns over in months. Whether retrieval actually grounds the answer — a tool can cite a source and still summarize it wrongly, which is why the documented "real-time citation validation" and clinician review steps 2 are substantive rather than decorative. When you evaluate one of these tools, evaluate its library and its retrieval, and treat the underlying model as the smaller variable.
The regulatory frame
Whether any of these tools is a regulated device resists a one-word answer. The FDA's clinical decision support guidance turns substantially on whether the software lets a clinician "independently review the basis" for its output rather than rely on it 6. A reference tool that surfaces sourced evidence for a clinician to weigh tends to sit on the non-device side of that line; a tool that directs a specific action, or whose basis cannot be independently checked, may not. Because the products add features continually, the regulatory analysis for a given tool can move — verify the current status rather than assuming the category answer.
How to choose for your setting
Ask questions, not for a ranking.
- Can you open the source? A linked, checkable citation 2 is worth more at the bedside than a marginally higher benchmark score.
- What is the evidence base, and how current is it? A curated, regularly refreshed base behaves differently from a general model's training data 23.
- Who may use it, and on what data? Access controls and data handling differ, and matter for compliance.
- Have you tested it on your own real questions? The benchmark used real physician queries for a reason 1; your specialty mix is the test that counts.
- Does it show its uncertainty? A tool that flags when evidence is thin is safer than one that always sounds certain.
- What happens on your specialties and edge cases? Aggregate benchmark performance 1 can hide weakness on the rare presentations where a reference tool is most needed, so probe the corners rather than the average.
How to read this comparison
Three cautions travel with the matrix. First, leaderboard position is the fastest-moving attribute here; the benchmark result 1 is a snapshot, and the general models and clinical tools are both re-tuned continually. Second, benchmark performance measures test-set answer quality, rather than live-clinic safety, workflow fit, or the value of an auditable citation trail. Third, the vendor-documented cells describe what each product says of itself; a claim of "citation validation" or "clinician-in-the-loop review" 2 is a starting point for your own verification rather than an audited fact. Fourth, product features, citations, and regulatory status change on the vendors' timelines, so every cell is dated July 2026, and availability and clearances change — reconfirm before you rely on any single cell. For the tools that draft notes rather than answer questions, see our AI scribe head-to-head comparison.
Sources and method
This comparison is anchored by one blinded benchmark that evaluated named specialized tools against frontier models 1, supported by a retrospective diagnostic-accuracy study 7, each vendor's own product documentation 2345, and the FDA's clinical decision support guidance 6. Every filled matrix cell is tied to one of these. We revisit this page on a 180-day cycle and whenever a new blinded benchmark or a documented change in retrieval, citation, or hallucination-control approach lands.